Thursday, October 11, 2012

GlaxoSmithKline paves the way for transparency in clinical trials

In a unique announcement, GlaxoSmithKline has stated that it will open up all data from the clinical trials they have conducted.  The goal is to promote collaboration and drive the discovery of new drugs.  GSK hopes that this new openness will give the transparency to see the operations of the industry, making an effort to show that Pharma companies are working ethically to develop drugs that will save lives around the world.

GSK CEO Andrew Witty stated "We've done an awful lot around this area but I think it's still fair to say that not everybody believes that everything is made public. Even things we do all the time we're criticised for not doing. People say we only publish positive trials. No, we publish everything. But the fact that people don't know or haven't yet accepted that we have this real commitment to transparency – we've got to keep working harder to get that message across."

The Guardian states that the company will open up an independent board to work with the scientists who would like to have access to the  data.  He hopes that by opening up access there is a greater probably of the discovery of new live-changing compounds to save more lives.  He believes this is the future of the Pharmaceutical business.

What does a decision like this mean for the industry?  Will more companies follow suit and open up their clinical trials data to all?




1 comment:

John said...

This is really worth reading, it has too much details in it and yet it is so simple to understand


Online GED Diploma